Stock listing

NASDAQ:INSM Insmed Incorporated Stock

Home listing (NASDAQ) of Insmed Incorporated

Follow Insmed Incorporated into a list and get an email when it puts out news.

Share price · NASDAQ:INSM

$141.33 USD +21.53 (+18.0%)

Close on Nov 20, 2026

Past year -29.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$140.99 – $150.00 USDNov 20, 2026
Volume
6.22M sharesNov 20, 2026
Market cap
$31.01B USDAt the close on Nov 20, 2026 · price × 219.4M shares outstanding
52-week range
$90.39 – $212.75 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$320.9M USDMedian day 2.47M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Insmed Incorporated logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:INSM · Home$141.33 USD+21.53 (+18.0%)6,215,617$143.98$150.00$140.99$119.80Close on Nov 20, 2026
LSE:0JAV$143.51 USD-0.29 (-0.2%)2,379$144.60$150.00$140.00$143.80Close on Nov 20, 2026
Frankfurt:IM8N€124.86 EUR+14.02 (+12.6%)—€109.80€124.86€109.80€110.84Close on Nov 19, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:INSM · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$141.33+21.53+18.0%$143.98$150.00$140.996,215,617
$119.80-2.06-1.7%$121.86$122.42$118.831,943,909
$121.86-1.02-0.8%$122.30$123.30$118.542,397,604
$122.88+1.72+1.4%$121.63$124.90$121.002,232,470
$121.16+3.09+2.6%$118.18$121.50$116.971,543,586
$118.07-2.68-2.2%$119.00$119.74$116.892,397,426
$120.75+1.26+1.1%$119.49$120.88$117.361,488,398
$119.49+3.39+2.9%$114.46$119.84$113.813,346,693
$116.10+1.695+1.5%$114.82$116.36$112.612,668,731
$114.41+5.645+5.2%$108.57$114.65$107.293,378,881
$108.76-1.24-1.1%$109.40$109.98$106.182,616,032
$110.00+5.56+5.3%$106.85$110.81$102.824,944,157
$104.44-4.87-4.5%$109.31$111.11$104.306,215,992
$109.31-3.27-2.9%$112.68$113.05$109.224,239,414
$112.58+0.99+0.9%$113.60$116.37$111.975,184,139
$111.59+14.61+15.1%$108.17$114.51$103.7811,217,794
$96.98+2.02+2.1%$94.01$97.92$93.914,646,019
$94.96+1.63+1.7%$93.33$96.34$92.873,348,161
$93.33-0.06-0.1%$94.02$94.34$92.963,379,731
$93.39-1.67-1.8%$94.12$94.64$92.633,410,530
$95.06+1.02+1.1%$93.50$95.59$93.333,099,798
$94.04-1.63-1.7%$95.08$97.09$93.802,970,356
$95.67+0.38+0.4%$95.44$97.20$94.602,612,666
$95.29-0.98-1.0%$96.27$97.88$94.382,723,597
$96.27-2.94-3.0%$98.70$99.00$96.052,396,400
$99.21+1.42+1.5%$99.26$100.72$97.903,346,600
$97.79+1.00+1.0%$97.39$98.00$95.762,736,400
$96.79-1.77-1.8%$98.18$99.73$96.542,161,100
$98.56-2.04-2.0%$98.82$100.31$98.331,696,000
$100.60+0.12+0.1%$100.52$101.82$99.152,474,300
$100.48-1.26-1.2%$100.66$101.06$96.685,251,800
$101.74-3.49-3.3%$103.87$104.80$101.603,164,000
$105.23+1.40+1.3%$103.97$107.87$101.323,685,700
$103.83-7.29-6.6%$105.50$108.75$101.655,394,700
$111.12+2.53+2.3%$107.76$111.54$105.684,136,200
$108.59-5.55-4.9%$114.68$116.19$108.482,646,300
$114.14-1.49-1.3%$115.65$116.43$113.602,868,400
$115.63-2.04-1.7%$117.06$118.50$114.491,668,200
$117.67-0.16-0.1%$116.83$119.32$116.311,744,400
$117.83-3.72-3.1%$121.87$122.90$115.872,672,700
$121.55+3.21+2.7%$119.26$121.69$118.382,233,600
$118.34-2.48-2.1%$121.58$122.65$116.741,921,600
$120.82-0.18-0.1%$121.00$122.48$119.092,405,300
$121.00+1.00+0.8%$123.06$124.48$120.921,811,900
$120.00-3.98-3.2%$123.89$124.11$119.323,443,200
$123.98+1.40+1.1%$124.16$127.40$122.881,591,800
$122.58+2.66+2.2%$120.00$124.41$119.551,433,800
$119.92-5.38-4.3%$126.10$126.10$118.343,364,300
$125.30-4.11-3.2%$129.50$130.78$124.581,610,500
$129.41+2.13+1.7%$127.98$130.25$126.521,698,200
$127.28-1.52-1.2%$127.22$128.85$124.292,594,500
$128.80+3.91+3.1%$124.00$130.83$121.042,841,800
$124.89-1.40-1.1%$124.78$127.42$121.381,604,100
$126.29-0.39-0.3%$126.00$128.24$125.621,802,700
$126.68+0.050.0%$126.70$127.09$124.051,885,200
$126.63+5.12+4.2%$121.11$126.79$121.111,998,200
$121.51-0.31-0.3%$121.95$122.19$119.521,419,300
$121.82+3.28+2.8%$118.68$122.71$117.512,389,700
$118.54-2.85-2.3%$120.11$120.66$117.151,977,500
$121.39-3.00-2.4%$124.67$126.10$121.211,056,100
$124.39+0.50+0.4%$122.89$125.59$121.641,979,900
$123.89-0.09-0.1%$124.65$127.18$122.872,373,100
$123.98-1.79-1.4%$125.03$126.11$122.831,340,900
$125.77+0.69+0.6%$125.22$127.20$124.821,124,500
$125.08-5.58-4.3%$128.36$130.27$124.601,761,700

Splits

2 splits since 2000 · NASDAQ:INSM · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
1-for-4Consolidation
Ticker
NASDAQ:INSM
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

Insmed Announces CFO Transition

Oct 5, 2026

Closed $103.83 (-6.6%) on Oct 5, 2026

All Insmed Incorporated news

Insmed Incorporated on 6ix

Sector
Health care
Industry
Biotechnology
News releases
33 in the last 12 months · 210 in all · newest Nov 4, 2026 · oldest 2019
Calls
23 calls with a replay · 23 with a transcript · latest Oct 29, 2026
Decks
50 decks · latest Oct 29, 2026

Where Insmed Incorporated is listed

ListingExchangeCountryCurrency
NASDAQ:INSM · Home listing · This pageNASDAQUnited StatesUSD
gettex:IM8NgettexGermanyEUR
Tradegate:IM8NTradegateGermanyEUR
LSE:0JAVLSEUnited KingdomUSD
LS Exchange:A1JJA3LS ExchangeGermanyEUR
BMV:INSMBMVMexicoMXN
BOATS:INSMBOATSUnited StatesUSD
Lang & Schwarz:A1JJA3Lang & SchwarzGermanyEUR
Milan:1INSMMilanItalyEUR
Stuttgart:IM8NStuttgartGermanyEUR
BIVA:INSMBIVAMexicoMXN
Frankfurt:IM8NFrankfurtGermanyEUR
BX Swiss:IM8NBX SwissSwitzerlandCHF
Hamburg:IM8NHamburgGermanyEUR
Dusseldorf:IM8NDusseldorfGermanyEUR
Hanover:IM8NHanoverGermanyEUR
Xetra:IM8NXetraGermanyEUR

Valuation

EV/sales 20.0× against a median of 8.1×: 8th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$30.41B USD
P/E
Loss
EV/sales
20.0×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
42.7×
Gross margin
84.4%
Operating margin
−37.1%
Net margin
−39.9%
Debt to equity
0.8×
Beta vs S&P 500
0.01

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Insmed Incorporated · NASDAQ:INSMUS$31.01BUS$30.41Bn/a20.0×n/a42.7×−39.9%0.8×0.01
CSL Limited · ASX:CSLUS$62.67BUS$72.05Bn/a4.6×14.3×4.2×−16.4%0.7×n/a
Biogen Inc. · NASDAQ:BIIBUS$36.89BUS$42.88B106×4.2×n/a1.9×3.4%0.4×0.34
Genmab A/S · OMXCOP:GMABUS$31.30BUS$34.64B42.9×8.1×24.4×4.9×17.0%0.8×n/a
Roivant Sciences Ltd. · NASDAQ:ROIVUS$27.92BUS$23.82Bn/a580×n/a7.0×−838.2%0.0×1.00
Alnylam Pharmaceuticals, Inc. · NASDAQ:ALNYUS$19.26BUS$15.68B7.3×n/an/a5.3×n/a0.0×0.58
Ascendis Pharma A/S · NASDAQ:ASNDUS$16.73BUS$16.15B17.1×12.2×61.1×10.0×73.5%0.3×0.49
Exelixis, Inc. · NASDAQ:EXELUS$15.77BUS$14.88B17.8×6.0×n/a8.6×35.4%0.0×0.69
Neurocrine Biosciences, Inc. · NASDAQ:NBIXUS$15.24BUS$14.50B21.7×3.9×n/a3.9×19.0%0.0×0.79
PharmaEssentia Corp. · TWSE:6446US$15.10BUS$14.39B65.3×22.9×56.4×13.5×36.8%0.0×n/a
BridgeBio Pharma, Inc. · NASDAQ:BBIOUS$14.86BUS$15.95Bn/a16.9×n/an/a−59.8%n/a0.89
Median of the othersUS$18.00BUS$16.05B21.7×8.1×40.4×5.3×17.0%0.0×0.69

Forecasts

18 strong buy · 5 buy · 1 hold · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
194.18 USD · Analysts' mean
EPS, year to Dec 2026
-1.67 · 17 analysts
Revenue, year to Dec 2026
1.86B · 20 analysts

Team and board

Officers

OfficerRole
William H. LewisChair and Chief Executive Officer
Roger AdsettChief Operating Officer
Michael SmithChief Legal Officer
Bryan DunnVice President, Investor Relations
Claire MulhearnVice President, Corporate Communications
Adele DeeringSenior Vice President, Portfolio Strategy & Operational Excellence
Samuele ButeraSenior Vice President, General Manager, Global Respiratory
Christie CamelioChief Compliance Officer
Eugene SullivanChief Product Strategy Officer
Kevin MangeChief Development Officer
Martina FlammerChief Medical Officer
Nicole SchaefferChief People Strategy Officer

Board

DirectorRole
William H. LewisChair and Chief Executive Officer
Carol A. SchaferDirector
Clarissa DesjardinsDirector
David R. BrennanLead Independent Director
Elizabeth McKee AndersonDirector
Gianna De PalmaAssociateDirector
Leo LeeDirector
Melvin SharokyDirector
Paul HudsonDirector
Utpal KoppikarDirector

Events

Calls

CallWhenStatus
Insmed (NASDAQ:INSM) Q3 2026 Earnings CallThu, Oct 29, 2026 · 8:00 AM ETReplay
Insmed (NASDAQ:INSM) Q2 2026 Earnings CallThu, Aug 06, 2026 · 8:00 AM ETReplay
Insmed (NASDAQ:INSM) Q1 2026 Earnings CallThu, May 07, 2026 · 8:00 AM ETReplay
Insmed (NASDAQ:INSM) Q4 2025 Earnings CallThu, Feb 19, 2026 · 8:00 AM ETReplay
Insmed (NASDAQ:INSM) Q3 2025 Earnings CallThu, Oct 30, 2025 · 8:00 AM ETReplay
Insmed (NASDAQ:INSM) Q2 2025 Earnings CallThu, Aug 07, 2025 · 8:00 AM ETReplay
Insmed (NASDAQ:INSM) Q1 2025 Earnings CallThu, May 08, 2025 · 8:00 AM ETReplay
Insmed (NASDAQ:INSM) Q4 2024 Earnings CallThu, Feb 20, 2025 · 8:00 AM ETReplay
Insmed (NASDAQ:INSM) Q3 2024 Earnings CallThu, Oct 31, 2024 · 8:00 AM ETReplay
Insmed (NASDAQ:INSM) Q2 2024 Earnings CallThu, Aug 08, 2024 · 8:00 AM ETReplay
All 23 calls
CallWhenStatus
Insmed (NASDAQ:INSM) Q1 2024 Earnings CallThu, May 09, 2024 · 8:00 AM ETReplay
Insmed (NASDAQ:INSM) Q4 2023 Earnings CallThu, Feb 22, 2024 · 8:30 AM ETReplay
Insmed (NASDAQ:INSM) Q3 2023 Earnings CallThu, Oct 26, 2023 · 8:30 AM ETReplay
Insmed (NASDAQ:INSM) Q2 2023 Earnings CallThu, Aug 03, 2023 · 8:30 AM ETReplay
Insmed (NASDAQ:INSM) Q1 2023 Earnings CallThu, May 04, 2023 · 8:30 AM ETReplay
Insmed (NASDAQ:INSM) Q4 2022 Earnings CallThu, Feb 23, 2023 · 8:30 AM ETReplay
Insmed (NASDAQ:INSM) Q2 2022 Earnings CallThu, Aug 04, 2022 · 8:30 AM ETReplay
Insmed (NASDAQ:INSM) Q1 2022 Earnings CallThu, May 05, 2022 · 8:30 AM ETReplay
Insmed (NASDAQ:INSM) Q4 2021 Earnings CallThu, Feb 17, 2022 · 9:30 AM ETReplay
Insmed (NASDAQ:INSM) Q3 2021 Earnings CallThu, Oct 28, 2021 · 8:30 AM ETReplay
Insmed (NASDAQ:INSM) Q2 2021 Earnings CallThu, Aug 05, 2021 · 8:30 AM ETReplay
Insmed (NASDAQ:INSM) Q4 2020 Earnings CallThu, Feb 25, 2021 · 8:30 AM ETReplay
Insmed (NASDAQ:INSM) Q3 2020 Earnings CallThu, Oct 29, 2020 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Oct 29, 2026 · Before open+15.1%
Q2 2026Aug 6, 2026 · Before open+33.9%
Q1 2026May 7, 2026 · Before open−23.4%
Q4 2025Feb 19, 2026 · Before open+6.5%
Q3 2025Oct 30, 2025 · Before open+16.3%
Q2 2025Aug 7, 2025 · Before open−1.8%
Q1 2025May 7, 2025 · Before open+0.6%
Q4 2024Feb 20, 2025 · Before open−0.3%
Q3 2024Oct 31, 2024 · Before open−4.3%
Q2 2024Aug 8, 2024 · Before open+1.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · Before open+1.5%
Q4 2023Feb 22, 2024 · Before open−3.9%
Q3 2023Oct 26, 2023 · Before open+0.4%
Q2 2023Aug 3, 2023 · Before open+1.8%
Q1 2023May 4, 2023 · Before open−1.2%
Q4 2022Feb 23, 2023 · Before open−2.5%
Q3 2022Oct 27, 2022 · Before open−4.1%
Q2 2022Aug 4, 2022 · Before open+15.2%
Q1 2022May 5, 2022 · Before open+0.7%
Q4 2021Feb 17, 2022 · Before open−2.0%

Open Events

Decks

DeckKindSlidesDate
Q3 2026 Earnings PresentationEarnings27 slidesOct 29, 2026
Investor Presentation (October 2026)Investor deck99 slidesOctober 2026
Q2 2026 Earnings PresentationEarnings27 slidesAug 6, 2026
Investor Presentation (August 2026)Investor deck97 slidesAugust 2026
Technical Presentation (July 2026)Technical27 slidesJul 16, 2026
Q1 2026 Earnings PresentationEarnings29 slidesMay 7, 2026
Technical Presentation (March 2026)Technical19 slidesMar 23, 2026
Q4 2025 Earnings PresentationEarnings24 slidesFeb 19, 2026
J.P. Morgan Healthcare Conference 2026Conference24 slidesJan 9, 2026
Fact Sheet (November 2025)Fact sheet1 slideNovember 2025
All 50 decks
DeckKindSlidesDate
Q3 2025 Earnings PresentationEarnings31 slidesOct 30, 2025
Fact Sheet (October 2025)Fact sheet2 slidesOctober 2025
Corporate Update (August 2025)Corporate update11 slidesAug 12, 2025
Q2 2025 Earnings PresentationEarnings21 slidesAug 7, 2025
Technical Presentation (June 2025)Technical19 slidesJun 10, 2025
Q1 2025 Earnings PresentationEarnings23 slidesMay 8, 2025
Investor Presentation (February 2025)Investor deck61 slidesFeb 20, 2025
JPMorgan Healthcare Conference 2025Conference30 slidesJan 10, 2025
7th World Bronchiectasis Conference (July 2024)Conference22 slidesJul 3, 2024
Investor Presentation (June 2024)Investor deck32 slidesJun 4, 2024
Technical Presentation (May 2024)Technical15 slidesMay 28, 2024
Technical Presentation (May 2024)Technical8 slidesMay 9, 2024
J.P. Morgan Healthcare Conference January 2024Conference17 slidesJan 5, 2024
Technical Presentation (September 2023)Technical18 slidesSep 5, 2023
Investor Day (May 2023)Investor day146 slidesMay 8, 2023
FY2022 Earnings PresentationEarnings18 slidesFeb 23, 2023
Investor Presentation (January 2023)Investor deck20 slidesJan 6, 2023
Earnings Presentation (February 2022)Earnings22 slidesFeb 17, 2022
Investor Presentation (January 2022)Investor deck46 slidesJan 10, 2022
Technical Presentation (February 2021)Technical23 slidesFeb 19, 2021
Investor Presentation (January 2021)Investor deck51 slidesJan 11, 2021
Investor Day (October 2020)Investor day114 slidesOct 1, 2020
Investor Presentation (February 2020)Investor deck33 slidesFeb 25, 2020
Investor Presentation (January 2020)Investor deck24 slidesJan 13, 2020
Investor Presentation (January 2019)Investor deck20 slidesJan 7, 2019
Investor Presentation (February 2018)Investor deck30 slidesFeb 14, 2018
Corporate Update (January 2018)Corporate update21 slidesJan 3, 2018
Technical Presentation (September 2017)Technical11 slidesSep 5, 2017
Investor Day (July 2017)Investor day149 slidesJul 19, 2017
Investor Day (March 2015)Investor day97 slidesMar 24, 2015
Investor Day (March 2015)Investor day95 slidesMar 24, 2015
Technical Presentation (July 2013)Technical5 slidesJul 1, 2013
Investor Presentation (December 2012)Investor deck41 slidesDec 3, 2012
IPO Roadshow (September 2012)IPO roadshow32 slidesSep 28, 2012
Investor Presentation (July 2012)Investor deck18 slidesJul 9, 2012
Investor Presentation (June 2012)Investor deck16 slidesJun 4, 2012
Investor Presentation (November 2011)Investor deck17 slidesNov 16, 2011
Investor Presentation (August 2011)Investor deck21 slidesAug 15, 2011
Investor Presentation (March 2011)Investor deck24 slidesMar 29, 2011
J.P. Morgan Healthcare Conference 2011Conference26 slidesJanuary 2011

Open Decks

Financings

RaiseDate
Public offering of common stock
Announced: about US$750M · US$96 a share · Goldman Sachs & Co. LLC +5
Dealers: Goldman Sachs & Co. LLC (lead), Leerink Partners (lead), BofA Securities (lead), Jefferies (lead), J.P. Morgan (lead), Stifel (co-lead)
Use of proceeds: R&D and commercialization of brensocatib, ARIKAYCE commercialization and development, TPIP, INS1201 and pre-clinical research, and general corporate purposes
Jun 11, 2025
Public offering of common stock
Announced: US$650M · Goldman Sachs & Co. LLC +1
Dealers: Goldman Sachs & Co. LLC (co-lead), Leerink Partners (co-lead)
Jun 11, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue606.4M363.7M305.2M245.4M188.5M164.4M136.5M9.84M00
Cost of revenue122.9M85.7M65.6M55.1M44.2M39.9M24.2M2.42M00
Gross profit483.5M278.0M239.6M190.2M144.3M124.5M112.3M7.41M00
Research and development771.1M598.4M571.0M397.5M272.7M181.2M131.7M145.3M109.7M122.7M
Selling, general and administrative701.2M461.1M344.5M265.8M
Operating income-1.25B-878.3M-709.6M-457.3M-375.1M-265.2M-235.2M-307.3M-188.9M-173.4M
Depreciation and amortization10.4M5.96M5.50M5.30M9.10M9.10M5.20M3.60M2.90M2.40M
EBITDA-1.24B-872.3M-704.1M-452.0M-366.0M-256.1M-230.0M-303.7M-186.0M-171.0M
Interest expense83.8M84.9M81.7M26.4M40.5M29.6M27.7M25.5M5.92M3.50M
Income before tax-1.27B-910.1M-747.0M-480.2M-436.4M-292.7M-253.6M-324.1M-192.9M-176.2M
Income tax5.03M3.71M2.56M1.38M-1.76M1.40M777.0K201.0K-272.0K98.0K
Net income-1.28B-913.8M-749.6M-481.5M-434.7M-294.1M-254.3M-324.3M-192.6M-176.3M
Earnings per share, basic-6.42-5.57-5.34-3.91-3.88-3.01-3.01-4.22-2.89-2.85
Earnings per share, diluted-6.42-5.57-5.34-3.91-3.88-3.01-3.01-4.22-2.89-2.85

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents510.4M555.0M482.4M1.07B716.8M532.8M487.4M495.1M381.2M162.6M
Short-term investments919.6M878.8M298.1M74.2M0
Receivables140.9M52.0M41.2M29.7M24.4M16.6M19.2M5.51M0
Inventory132.1M98.6M83.2M69.9M67.0M49.6M28.3M7.03M0
Current assets1.79B1.62B929.1M1.27B837.0M622.9M555.2M518.9M389.4M168.4M
Property, plant and equipment102.9M80.1M65.4M56.5M53.0M54.0M60.2M22.6M12.4M10.0M
Goodwill136.1M136.1M136.1M136.1M136.1M0
Total assets2.26B2.03B1.33B1.66B1.24B796.2M742.3M604.6M462.0M238.0M
Accounts payable79.9M73.0M65.4M50.5M35.8M42.9M13.2M17.7M14.7M10.4M
Current liabilities468.9M297.5M225.6M190.2M135.2M118.8M85.2M79.7M44.7M28.0M
Long-term debt541.0M1.10B1.16B1.13B566.6M356.3M335.9M316.6M55.6M54.8M
Total debt546.8M1.12B1.18B1.15B800.0M450.0M450.0M450.0M55.0M55.0M
Total liabilities1.53B1.74B1.66B1.57B833.0M520.3M480.6M396.3M101.0M83.5M
Shareholders' equity739.0M285.4M-331.9M88.0M410.5M275.9M261.7M208.3M361.1M154.5M
Shares outstanding214.3M179.4M148.0M135.7M118.7M102.8M89.7M77.3M76.6M62.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-935.0M-683.9M-536.2M-400.4M-363.3M-219.3M-250.6M-258.0M-159.6M-146.7M
Capital spending-32.6M-21.9M-13.3M-9.88M-7.29M-6.24M-42.3M-13.1M-3.00M-4.20M
Free cash flow-967.6M-705.8M-549.5M-410.3M-370.6M-225.6M-292.9M-271.1M-162.6M-150.9M
Cash from investing-64.6M-583.2M-223.6M-34.6M-64.3M-6.82M-42.3M-14.8M-3.00M-4.20M
Cash from financing954.1M1.34B168.4M793.3M612.5M271.0M285.3M386.7M381.1M30.7M
Change in cash-44.6M72.7M-591.7M357.3M184.0M45.3M-7.64M113.9M218.6M-120.3M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 20, 2026Insider tradeSEC
144 · Notice of proposed saleNov 19, 2026Other filingsSEC
144 · Notice of proposed saleNov 3, 2026Other filingsSEC
3 · Initial statement of ownershipNov 3, 2026Insider tradeSEC
8-K · Current reportOct 29, 2026ResultsSEC
10-Q · Quarterly reportOct 29, 2026Quarterly reportSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 20, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 20, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportOct 20, 2026Management or board changeSEC
8-K · Current reportOct 5, 2026Management or board changeSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
144 · Notice of proposed saleSep 10, 2026Other filingsSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
144 · Notice of proposed saleAug 10, 2026Other filingsSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
144 · Notice of proposed saleAug 6, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2026Big-stake noticeSEC
8-K · Current reportAug 6, 2026ResultsSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
4 · Change in ownershipJul 24, 2026Insider tradeSEC
144 · Notice of proposed saleJul 23, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 22, 2026Big-stake noticeSEC
8-K · Current reportJul 16, 2026Current reportSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
144 · Notice of proposed saleJul 9, 2026Other filingsSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
144 · Notice of proposed saleJun 25, 2026Other filingsSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
144 · Notice of proposed saleJun 22, 2026Other filingsSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
144 · Notice of proposed saleJun 8, 2026Other filingsSEC
144 · Notice of proposed saleJun 5, 2026Other filingsSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
144 · Notice of proposed saleJun 3, 2026Other filingsSEC
144 · Notice of proposed saleJun 3, 2026Other filingsSEC
144 · Notice of proposed saleJun 3, 2026Other filingsSEC
144 · Notice of proposed saleJun 3, 2026Other filingsSEC
144 · Notice of proposed saleJun 3, 2026Other filingsSEC
144 · Notice of proposed saleMay 22, 2026Other filingsSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
144 · Notice of proposed saleMay 18, 2026Other filingsSEC
S-3ASR · Registration statementMay 15, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
8-K · Current reportMay 15, 2026Meeting outcomeSEC
144 · Notice of proposed saleMay 14, 2026Other filingsSEC
144 · Notice of proposed saleMay 13, 2026Other filingsSEC
144 · Notice of proposed saleMay 13, 2026Other filingsSEC
144 · Notice of proposed saleMay 13, 2026Other filingsSEC
144 · Notice of proposed saleMay 13, 2026Other filingsSEC
144 · Notice of proposed saleMay 13, 2026Other filingsSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
144 · Notice of proposed saleMay 11, 2026Other filingsSEC
8-K · Current reportMay 7, 2026ResultsSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 6, 2026Big-stake noticeSEC
144 · Notice of proposed saleMay 4, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeApr 30, 2026Big-stake noticeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
144 · Notice of proposed saleApr 16, 2026Other filingsSEC
4 · Change in ownershipApr 8, 2026Insider tradeSEC
8-K · Current reportApr 7, 2026Current reportSEC
144 · Notice of proposed saleApr 6, 2026Other filingsSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
144 · Notice of proposed saleApr 1, 2026Other filingsSEC
ARS · Annual report to shareholdersApr 1, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 1, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 1, 2026Meeting noticeSEC
4 · Change in ownershipMar 31, 2026Insider tradeSEC
144 · Notice of proposed saleMar 30, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
8-K · Current reportMar 23, 2026Current reportSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
144 · Notice of proposed saleMar 19, 2026Other filingsSEC
144 · Notice of proposed saleMar 5, 2026Other filingsSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 25, 2026Insider tradeSEC
4 · Change in ownershipFeb 25, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 24, 2026Other filingsSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 19, 2026Other filingsSEC
10-K · Annual reportFeb 19, 2026Annual reportSEC
8-K · Current reportFeb 19, 2026ResultsSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 9, 2026Other filingsSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 5, 2026Other filingsSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 3, 2026Other filingsSEC
144 · Notice of proposed saleFeb 3, 2026Other filingsSEC
144 · Notice of proposed saleFeb 3, 2026Other filingsSEC
144 · Notice of proposed saleFeb 3, 2026Other filingsSEC
144 · Notice of proposed saleFeb 3, 2026Other filingsSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 21, 2026Big-stake noticeSEC
144 · Notice of proposed saleJan 20, 2026Other filingsSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
144 · Notice of proposed saleJan 12, 2026Other filingsSEC
8-K · Current reportJan 9, 2026Current reportSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
144 · Notice of proposed saleJan 7, 2026Other filingsSEC
144 · Notice of proposed saleJan 7, 2026Other filingsSEC
144 · Notice of proposed saleJan 7, 2026Other filingsSEC
144 · Notice of proposed saleJan 7, 2026Other filingsSEC
144 · Notice of proposed saleJan 7, 2026Other filingsSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
144 · Notice of proposed saleJan 5, 2026Other filingsSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
144 · Notice of proposed saleDec 18, 2025Other filingsSEC
8-K · Current reportDec 17, 2025Current reportSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
144 · Notice of proposed saleDec 5, 2025Other filingsSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC
144 · Notice of proposed saleDec 4, 2025Other filingsSEC
4 · Change in ownershipDec 3, 2025Insider tradeSEC
144 · Notice of proposed saleDec 1, 2025Other filingsSEC
4 · Change in ownershipNov 26, 2025Insider tradeSEC
144 · Notice of proposed saleNov 24, 2025Other filingsSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
8-K · Current reportNov 18, 2025Current reportSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
144 · Notice of proposed saleNov 13, 2025Other filingsSEC
144 · Notice of proposed saleNov 12, 2025Other filingsSEC
144 · Notice of proposed saleNov 12, 2025Other filingsSEC
4 · Change in ownershipNov 10, 2025Insider tradeSEC
4 · Change in ownershipNov 5, 2025Insider tradeSEC
144 · Notice of proposed saleNov 3, 2025Other filingsSEC
10-Q · Quarterly reportOct 30, 2025Quarterly reportSEC
8-K · Current reportOct 30, 2025ResultsSEC
4 · Change in ownershipSep 15, 2025Insider tradeSEC
4 · Change in ownershipSep 15, 2025Insider tradeSEC
144 · Notice of proposed saleSep 12, 2025Other filingsSEC
144 · Notice of proposed saleSep 12, 2025Other filingsSEC
4 · Change in ownershipSep 5, 2025Insider tradeSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedSep 4, 2025Big-stake noticeSEC
144 · Notice of proposed saleSep 2, 2025Other filingsSEC
144 · Notice of proposed saleSep 2, 2025Other filingsSEC
4 · Change in ownershipAug 21, 2025Insider tradeSEC

This page holds 200 of 1,013 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Insmed Incorporated’s releases · as of Oct 23, 2026

Common shares
219,380,309
Fully diluted
219,380,309

Fully diluted

LineSharesAs of
Common shares219,380,309Oct 23, 2026

Share count over time

CountShares
Oct 23, 2026219,380,309

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard22.5M10.2%US$2.56BSep 30, 2026
BlackRock15.9M7.3%US$1.82BSep 30, 2026
Fidelity15.5M7.1%US$1.77BSep 30, 2026
Capital Group9.35M4.3%US$1.07BSep 30, 2026
Baker Bros. Advisors LP8.8M4.0%US$1BSep 30, 2026
JPMorgan8.24M3.8%US$953MSep 30, 2026
Orbis Allan Gray Ltd6.73M3.1%US$769MSep 30, 2026
Ameriprise6.25M2.8%US$713MSep 30, 2026
State Street6.16M2.8%US$703MSep 30, 2026
Artisan Partners Limited Partnership5.58M2.5%US$637MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
AQR Capital Management LLC5.21M2.4%US$595MSep 30, 2026
T. Rowe Price4.82M2.2%US$551MSep 30, 2026
Janus Henderson4.31M2.0%US$492MSep 30, 2026
Geode Capital4.15M1.9%US$473MSep 30, 2026
D. E. Shaw & Co., Inc.3.84M1.8%US$439MSep 30, 2026
Rtw Investments, LP3.1M1.4%US$353MSep 30, 2026
Franklin Templeton2.93M1.3%US$325MSep 30, 2026
UBS2.73M1.2%US$311MSep 30, 2026
Vestal Point Capital, LP2.73M1.2%US$311MSep 30, 2026
Paradigm Biocapital Advisors LP2.7M1.2%US$308MSep 30, 2026
Castle Hook Partners LP2.56M1.2%US$292MSep 30, 2026
Maverick Capital LTD2.52M1.1%US$288MSep 30, 2026
Pictet Asset Management Holding SA1.76M0.80%US$201MSep 30, 2026
Polar Capital Holdings Plc1.75M0.80%US$200MSep 30, 2026
Integral Health Asset Management, LLC1.6M0.73%US$129MSep 30, 2026
Westfield Capital Management Co LP1.55M0.71%US$177MSep 30, 2026
RBC1.53M0.70%US$174MSep 30, 2026
Bellevue Group AG1.51M0.69%US$172MSep 30, 2026
Deep Track Capital, LP1.35M0.62%US$154MSep 30, 2026
Northern Trust1.3M0.59%US$149MSep 30, 2026
BNY1.29M0.59%US$147MSep 30, 2026
Assenagon Asset Management S.A.1.27M0.58%US$145MSep 30, 2026
Amundi1.25M0.57%US$143MSep 30, 2026
Adage Capital Partners Gp, L.L.C.1.25M0.57%US$143MSep 30, 2026
Sei Investments Co1.21M0.55%US$138MSep 30, 2026
Morgan Stanley1.16M0.53%US$132MSep 30, 2026
BNP Paribas1.1M0.50%US$125MSep 30, 2026
Duquesne Family Office LLC1.09M0.50%US$125MSep 30, 2026
Hood River Capital Management LLC1.08M0.49%US$123MSep 30, 2026
FIL Ltd1.07M0.49%US$123MSep 30, 2026
Schwab1.07M0.49%US$122MSep 30, 2026
Holocene Advisors, LP1.05M0.48%US$120MSep 30, 2026
Bank of America993K0.45%US$113MSep 30, 2026
Qube Research & Technologies Ltd987K0.45%US$113MSep 30, 2026
Railway Pension Investments Ltd869K0.40%US$99.1MSep 30, 2026
Fiera Capital Corp866K0.39%US$98.8MSep 30, 2026
Jennison Associates LLC857K0.39%US$97.8MSep 30, 2026
Jane Street820K0.37%US$93.7MSep 30, 2026
abrdn810K0.37%US$92.4MSep 30, 2026
Legal & General793K0.36%US$90.5MSep 30, 2026

This page holds 50 of 689 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund6.88M3.1%US$734MJun 30, 2026
Growth Fund of America6.25M2.9%US$669MMay 31, 2026
JPMorgan Large Cap Growth Fund2.79M1.3%US$297MJun 30, 2026
Vanguard Small-Cap Index Fund2.49M1.1%US$265MJun 30, 2026
Vanguard Extended Market Index Fund2.49M1.1%US$265MJun 30, 2026
Vanguard Mid-Cap Index Fund2.35M1.1%US$250MJun 30, 2026
Vanguard Growth Index Fund1.8M0.82%US$192MJun 30, 2026
iShares Biotechnology ETF1.52M0.69%US$162MJun 30, 2026
JPMorgan Mid Cap Growth Fund1.43M0.65%US$153MJun 30, 2026
Vanguard Small-Cap Growth Index Fund1.43M0.65%US$153MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
JPMorgan Growth Advantage Fund1.38M0.63%US$147MJun 30, 2026
iShares Russell Mid-Cap Growth ETF1.27M0.58%US$135MJun 30, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund1.26M0.57%US$135MMay 31, 2026
Select Biotechnology Portfolio1.11M0.51%US$119MMay 31, 2026
Fidelity Extended Market Index Fund1.1M0.50%US$117MMay 31, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1.08M0.49%US$116MJun 30, 2026
Growth Fund1.03M0.47%US$110MJun 30, 2026
Invesco NASDAQ 100 ETF916K0.42%US$97.9MMay 31, 2026
Fidelity Advisor Growth Opportunities Fund905K0.41%US$96.8MMay 31, 2026
iShares Russell Mid-Cap ETF881K0.40%US$93.9MJun 30, 2026
T. Rowe Price Mid-Cap Growth Fund, Inc.864K0.39%US$92.1MJun 30, 2026
Fidelity Puritan Fund849K0.39%US$90.8MMay 31, 2026
Vanguard Mid-Cap Growth Index Fund830K0.38%US$88.5MJun 30, 2026
iShares Russell 1000 Growth ETF819K0.37%US$87.3MJun 30, 2026
Fidelity Mid Cap Index Fund813K0.37%US$80.1MJul 31, 2026
SMALLCAP World Fund Inc717K0.33%US$76.4MJun 30, 2026
Artisan Mid Cap Fund709K0.32%US$75.6MJun 30, 2026
Fidelity Advisor Biotechnology Fund680K0.31%US$67.1MJul 31, 2026
Heritage Fund647K0.29%US$63.8MJul 31, 2026
Vanguard Health Care Index Fund640K0.29%US$68.5MMay 31, 2026
Bridge Builder Small/Mid Cap Growth Fund603K0.28%US$64.3MJun 30, 2026
Columbia Cornerstone Growth Fund587K0.27%US$57.9MJul 31, 2026
Fidelity Growth Company Fund566K0.26%US$60.6MMay 31, 2026
T. Rowe Price Health Sciences Fund, Inc.548K0.25%US$58.5MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.508K0.23%US$54.2MJun 30, 2026
Columbia Contrarian Core Fund507K0.23%US$54.2MMay 31, 2026
Fidelity Advisor Equity Growth Fund502K0.23%US$53.7MMay 31, 2026
Select Health Care Portfolio500K0.23%US$53.5MMay 31, 2026
T. Rowe Price All-Cap Opportunities Fund462K0.21%US$49.2MJun 30, 2026
Schwab U.S. Large-Cap Growth ETF455K0.21%US$48.6MMay 31, 2026
VIP Growth Portfolio435K0.20%US$46.4MJun 30, 2026
JPMorgan Active Growth ETF421K0.19%US$44.9MJun 30, 2026
Fidelity Total Market Index Fund404K0.18%US$43.2MMay 31, 2026
Eventide Healthcare & Life Sciences Fund403K0.18%US$43MJun 30, 2026
BlackRock Health Sciences Opportunities Portfolio392K0.18%US$41.9MMay 29, 2026
JNL/JPMorgan MidCap Growth Fund392K0.18%US$41.8MJun 30, 2026
Hood River Small-Cap Growth Fund387K0.18%US$41.2MJun 30, 2026
Fidelity OTC Portfolio384K0.18%US$37.9MJul 31, 2026
Vanguard Explorer Fund381K0.17%US$37.6MJul 31, 2026
Carillon Eagle Mid Cap Growth Fund374K0.17%US$39.9MJun 30, 2026

This page holds 50 of 623 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Schaeffer Orlov S Nicole
Officer: Chief People Strategy Officer
Sale90,299USD 145.06US$13.1MNov 19, 2026
Schaeffer Orlov S Nicole
Officer: Chief People Strategy Officer
Sale8,539USD 146.76US$1.25MNov 19, 2026
Schaeffer Orlov S Nicole
Officer: Chief People Strategy Officer
Sale2,262USD 147.50US$334KNov 19, 2026
Brennan David R
Director
Sale25,000USD 124.00US$3.1MSep 9, 2026
Sharoky Melvin Md
Director
Sale5,000USD 127.53US$638KAug 17, 2026
Adsett Roger
Officer: Chief Operating Officer
Sale239,850USD 133.27US$32MAug 10, 2026
Flammer Martina M.D.
Officer: Chief Medical Officer
Sale8,895USD 127.00US$1.13MAug 6, 2026
Flammer Martina M.D.
Officer: Chief Medical Officer
Sale18,278USD 129.40US$2.37MAug 6, 2026
Lewis William
Director, Officer: Chair and CEO
Sale4,828USD 105.62US$510KJul 23, 2026
Lewis William
Director, Officer: Chair and CEO
Sale5,872USD 106.43US$625KJul 23, 2026
Show 50 trades
TradeTradeSharesPriceValueDate
Lewis William
Director, Officer: Chair and CEO
Sale5,005USD 116.55US$583KJul 9, 2026
Lewis William
Director, Officer: Chair and CEO
Sale2,335USD 117.62US$275KJul 9, 2026
Lewis William
Director, Officer: Chair and CEO
Sale3,359USD 118.52US$398KJul 9, 2026
Flammer Martina M.D.
Officer: Chief Medical Officer
Sale4,854USD 109.02US$529KJul 6, 2026
Flammer Martina M.D.
Officer: Chief Medical Officer
Sale7,448USD 110.60US$824KJul 6, 2026
Lewis William
Director, Officer: Chair and CEO
Sale12,091USD 102.34US$1.24MJun 25, 2026
Lewis William
Director, Officer: Chair and CEO
Sale1,836USD 103.10US$189KJun 25, 2026
Lewis William
Director, Officer: Chair and CEO
Sale3,723USD 104.28US$388KJun 25, 2026
Lewis William
Director, Officer: Chair and CEO
Sale2,456USD 105.27US$259KJun 25, 2026
Lewis William
Director, Officer: Chair and CEO
Sale1,292USD 106.27US$137KJun 25, 2026
Smith Michael Alexander
Officer: Chief Legal Officer
Sale1,806USD 95.82US$173KJun 22, 2026
Lewis William
Director, Officer: Chair and CEO
Sale6,515USD 94.03US$613KJun 8, 2026
Flammer Martina M.D.
Officer: Chief Medical Officer
Sale1,858USD 103.78US$193KJun 5, 2026
Lewis William
Director, Officer: Chair and CEO
Sale7,605USD 102.27US$778KJun 3, 2026
Bonstein Sara
Officer: Chief Financial Officer
Sale2,404USD 102.27US$246KJun 3, 2026
Adsett Roger
Officer: Chief Operating Officer
Sale2,370USD 102.27US$242KJun 3, 2026
Flammer Martina M.D.
Officer: Chief Medical Officer
Sale2,566USD 102.27US$262KJun 3, 2026
Smith Michael Alexander
Officer: Chief Legal Officer
Sale2,159USD 102.27US$221KJun 3, 2026
Smith Michael Alexander
Officer: Chief Legal Officer
Sale6,149USD 108.47US$667KMay 22, 2026
Lewis William
Director, Officer: Chair and CEO
Sale5,753USD 105.32US$606KMay 18, 2026
Lewis William
Director, Officer: Chair and CEO
Sale11,836USD 106.39US$1.26MMay 18, 2026
Lewis William
Director, Officer: Chair and CEO
Sale7,975USD 106.97US$853KMay 18, 2026
Flammer Martina M.D.
Officer: Chief Medical Officer
Sale10,479USD 117.54US$1.23MMay 14, 2026
Lewis William
Director, Officer: Chair and CEO
Sale13,283USD 116.18US$1.54MMay 13, 2026
Bonstein Sara
Officer: Chief Financial Officer
Sale8,272USD 116.18US$961KMay 13, 2026
Adsett Roger
Officer: Chief Operating Officer
Sale5,837USD 116.18US$678KMay 13, 2026
Flammer Martina M.D.
Officer: Chief Medical Officer
Sale4,470USD 112.76US$504KMay 13, 2026
Flammer Martina M.D.
Officer: Chief Medical Officer
Sale3,384USD 116.18US$393KMay 13, 2026
Smith Michael Alexander
Officer: Chief Legal Officer
Sale4,109USD 116.18US$477KMay 13, 2026
Flammer Martina M.D.
Officer: Chief Medical Officer
Sale12,119USD 100.35US$1.22MMay 11, 2026
Flammer Martina M.D.
Officer: Chief Medical Officer
Sale830USD 101.18US$83,979May 11, 2026
Lewis William
Director, Officer: Chair and CEO
Sale433USD 134.18US$58,100May 4, 2026
Lewis William
Director, Officer: Chair and CEO
Sale599USD 135.18US$80,973May 4, 2026
Lewis William
Director, Officer: Chair and CEO
Sale5,318USD 137.01US$729KMay 4, 2026
Lewis William
Director, Officer: Chair and CEO
Sale2,721USD 137.86US$375KMay 4, 2026
Lewis William
Director, Officer: Chair and CEO
Sale1,247USD 139.09US$173KMay 4, 2026
Lewis William
Director, Officer: Chair and CEO
Sale381USD 139.60US$53,188May 4, 2026
Lewis William
Director, Officer: Chair and CEO
Sale2,246USD 142.99US$321KApr 16, 2026
Lewis William
Director, Officer: Chair and CEO
Sale5,373USD 143.81US$773KApr 16, 2026
Lewis William
Director, Officer: Chair and CEO
Sale2,255USD 144.66US$326KApr 16, 2026

This page holds 50 of 57 trades. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
FMR LLC7.40%16.1MJun 30, 2026Schedule 13G
BlackRock, Inc.6.60%14.1MDec 31, 2025Schedule 13G
Vanguard Capital Management LLC5.34%11.5MMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Myrtle S Potter
Other companies: Ginkgo Bioworks Holdings, Inc. (Director · Since at least Jun 13, 2024); Guardant Health, Inc. (Director · Since at least Oct 15, 2021); Immunovant, Inc. (Director · Dec 18, 2019 – Dec 18, 2019 · Past); Arbutus Biopharma Corporation (Director · Oct 18, 2018 – Aug 17, 2019 · Past); Sio Gene Therapies Inc (Director · Sep 26, 2018 – Apr 15, 2019 · Past); Urovant Sciences Ltd (Director · Sep 26, 2018 – Mar 29, 2021 · Past); Myovant Sciences Ltd (Director · Sep 20, 2018 – Mar 10, 2023 · Past); Axsome Therapeutics, Inc. (Director · Jun 16, 2017 – Jun 7, 2019 · Past); Everyday Health Inc (Director · Mar 27, 2014 – Dec 3, 2016 · Past); Rite Aid Corporation (Director · Nov 29, 2013 – Oct 3, 2017 · Past)
Director · Dec 11, 2014 – May 15, 2018 · Past
Christine Pellizzari
Other companies: NeuroSense Therapeutics Ltd. (Board Member · Since at least Mar 18, 2026); Tempest Therapeutics, Inc. (Director · Since at least Jul 1, 2021); Imunon, Inc. (Director · Since at least Jun 8, 2021); LifeSci Acquisition II Corp (Chief Legal and HR Officer · Oct 6, 2021 – Mar 12, 2024 · Past); Aegerion Pharmaceuticals Inc (EVP, Gen. Counsel & Secretary · Oct 21, 2010 – Oct 21, 2010 · Past); Dendrite International Inc (Sr VP, General Counsel & Secty · May 1, 2006 – May 9, 2007 · Past)
Chief Legal Officer · Jul 29, 2013 – May 15, 2021 · Past
Carol A. Schafer
Other companies: Immunome, Inc. (Director · Since at least Jan 2, 2024); Kura Oncology, Inc. (Director · Since at least Jun 3, 2021); Repare Therapeutics Inc (Director · Since at least May 13, 2021); Five Prime Therapeutics Inc (Director · Apr 16, 2021 – Apr 16, 2021 · Past); Aceragen Inc. (Director · Oct 1, 2020 – Jun 23, 2022 · Past)
Director · Since at least May 12, 2021
David McGirr
Other companies: X4 Pharmaceuticals, Inc. (Director · Since at least Nov 15, 2017); Rhythm Pharmaceuticals, Inc. (Director · Since at least Oct 4, 2017); Roka Bioscience Inc (Director · Jul 16, 2014 – Jun 28, 2017 · Past); Relypsa Inc (Director · Nov 14, 2013 – Sep 1, 2016 · Past); Cubist Pharmaceuticals Inc (SVP & Chief Financial Officer · Mar 31, 2010 – Feb 15, 2013 · Past)
Director · Since at least Oct 30, 2013
Richard S Kollender
Other companies: Rapid Micro Biosystems, Inc. (Director · Since at least Jul 14, 2021); Strongbridge Biopharma plc (President and CFO · Jan 1, 2018 – Oct 5, 2021 · Past); Celator Pharmaceuticals Inc (Director · Jan 14, 2013 – Jun 20, 2016 · Past); NuPathe Inc. (Director · Aug 5, 2010 – Feb 21, 2014 · Past)
Director · Jan 12, 2011 – Oct 31, 2013 · Past
Stephen C. Glover
Other companies: Oncolytics Biotech Inc. (Director · Since at least Jun 1, 2026); ZyVersa Therapeutics, Inc. (Co-founder, Chairman, CEO, and President · Since at least Dec 12, 2022); PDS Biotechnology Corporation (Director · Since at least Apr 2, 2019); Ambrx Biopharma Inc. (Director · May 18, 2023 – Mar 7, 2024 · Past)
President Follow-on Biologics · Jun 22, 2007 – Mar 31, 2009 · Past
Alfred Altomari
Other companies: Recro Pharma Inc (Director · Mar 12, 2014 – Dec 5, 2019 · Past); Auxilium Pharmaceuticals Inc (Director · Jun 6, 2006 – Jun 16, 2011 · Past); Barrier Therapeutics Inc (Chief Executive Officer, Director · Mar 31, 2006 – Aug 5, 2008 · Past)
Director · Aug 2, 2012 – May 13, 2024 · Past
Donald J Hayden Jr
Other companies: Theseus Pharmaceuticals Inc (Director · May 17, 2022 – Feb 14, 2024 · Past); Amicus Therapeutics Inc (Director · Jan 2, 2018 – Jun 7, 2018 · Past); Regenxbio Inc. (Director · Oct 11, 2017 – May 29, 2020 · Past)
Director · Nov 14, 2017 – Apr 9, 2019 · Past
Paul Streck
Other companies: PepGen Inc. (Executive Vice President, Head of Research & Development · Since at least Aug 19, 2024); Albireo Pharma Inc (Chief Medical Officer · Dec 19, 2022 – Mar 2, 2023 · Past); Alder BioPharmaceuticals Inc (Chief Medical Officer · Jan 21, 2019 – Oct 22, 2019 · Past)
Chief Medical Officer · Jun 5, 2017 – Aug 8, 2018 · Past
Sara Bonstein
Other companies: Latigo Biotherapeutics, Inc. (Director · Since at least Aug 6, 2026); Xilio Therapeutics, Inc. (Chair of the Board · Since at least Jun 15, 2022); Scpharmaceuticals Inc (Director · Since at least Jun 14, 2022)
Chief Financial Officer · Since at least May 11, 2022
All 46 people
PersonSeat
Utpal Koppikar
Other companies: C4 Therapeutics, Inc. (Director · Since at least Mar 16, 2022); Flexion Therapeutics Inc (Director · Jul 9, 2021 – Nov 19, 2021 · Past); Atara Biotherapeutics, Inc. (Chief Financial Officer · Jun 7, 2018 – Mar 2, 2023 · Past)
Director · Since at least Oct 19, 2026
William H. Lewis
Other companies: NewAmsterdam Pharma Company N.V. (Director · Since at least Jan 4, 2024); uniQure N.V. (Director · Jan 1, 2017 – Jan 27, 2017 · Past); Aegerion Pharmaceuticals Inc (President, PFO and Treasurer · Oct 21, 2010 – Oct 27, 2010 · Past)
Chair and Chief Executive Officer · Since at least Sep 10, 2012
Elizabeth McKee Anderson
Other companies: Revolution Medicines, Inc. (Director · Since at least Feb 12, 2020); BioMarin Pharmaceutical Inc. (Director · Since at least Jul 8, 2019)
Director · Since at least Nov 6, 2018
Melvin Sharoky
Other companies: Par Pharmaceutical Companies Inc (Director · Mar 8, 2007 – Sep 28, 2012 · Past); Andrx Corp (Director · Feb 28, 2006 – Nov 3, 2006 · Past)
Director · Since at least May 10, 2006
Renu Gupta
Other companies: Corbus Pharmaceuticals Holdings, Inc. (Director · Nov 24, 2014 – May 25, 2017 · Past); Agenus Inc. (Sr. VP Development · Feb 24, 2006 – Jul 20, 2006 · Past)
Executive Vice President & CMO · Dec 1, 2010 – Jan 31, 2014 · Past
Roger Adsett
Other companies: Definium Therapeutics, Inc. (Director · Since at least Jan 29, 2026); Landos Biopharma Inc (Director · Mar 8, 2022 – May 23, 2024 · Past)
Chief Operating Officer · Since at least Sep 27, 2016
Clarissa Desjardins
Other companies: Xenon Pharmaceuticals Inc. (Director · Jan 13, 2020 – Jun 1, 2020 · Past)
Director · Since at least Nov 12, 2019
Dennis M. Lanfear
Other companies: Coherus Oncology, Inc. (President & Chief Executive Officer · Since at least Nov 6, 2014)
Director · Dec 6, 2007 – Jun 9, 2010 · Past
John Goll
Other companies: Immunocore Holdings plc (SVP, FINANCE & CAO · Since at least Jan 2, 2024)
Chief Accounting Officer · Jun 3, 2019 – Jan 3, 2020 · Past
Orlov S Nicole Schaeffer
Other companies: Amicus Therapeutics Inc (SVP, HR & Leadership Devt · Feb 3, 2009 – Feb 15, 2012 · Past)
Chief People Strategy Officer · Since at least Jun 2, 2014
Randall W Whitcomb
Other companies: Tempest Therapeutics, Inc. (Director · Dec 7, 2018 – Jun 20, 2019 · Past)
Director · Jan 10, 2014 – Mar 10, 2015 · Past
Adele DeeringSenior Vice President, Portfolio Strategy & Operational Excellence · Since at least Nov 4, 2026
Andrea Holtzman DruckerSVP, Gen. Counsel & Corp Sec. · Jul 18, 2011 – Jun 3, 2013 · Past
Bryan DunnVice President, Investor Relations · Since at least Aug 6, 2026
Christie CamelioChief Compliance Officer · Since at least Nov 5, 2026
Claire MulhearnVice President, Corporate Communications · Since at least Aug 6, 2026
David R. BrennanLead Independent Director · Since at least May 11, 2022
Doug FarrarVice President, ITP · Nov 1, 2006 – Mar 31, 2009 · Past
Eugene SullivanChief Product Strategy Officer · Since at least Mar 23, 2015
Geoffrey AllanPresident, CEO and Chairman, Director · Jun 21, 2007 – Mar 31, 2009 · Past
Gianna De PalmaAssociateDirector · Since at least Oct 20, 2026
Glen L KelleyVP, REGULATORY AFFAIRS · Mar 31, 2009 – Mar 31, 2009 · Past
John Drayton WiseChief Commercial Officer · May 23, 2022 – Feb 5, 2025 · Past
John SorianoChief Compliance Officer · Jan 3, 2021 – Sep 7, 2021 · Past
Kenneth G CondonDirector · May 9, 2007 – Jun 9, 2010 · Past
Kevin MangeChief Development Officer · Since at least Nov 5, 2026
Kevin P TullyExecutive VP & CFO · Feb 20, 2006 – Dec 21, 2011 · Past
Leo LeeDirector · Since at least May 15, 2018
Martina FlammerChief Medical Officer · Since at least Dec 16, 2019
Michael SmithChief Legal Officer · Since at least Jul 8, 2021
Nicholas Lee GurreriSenior VP, Commercial Ops · Jan 31, 2011 – Jan 31, 2011 · Past
Nicole SchaefferChief People Strategy Officer · Since at least Sep 16, 2026
Paul HudsonDirector · Since at least Oct 19, 2026
Peggy BerryVice President, Regulatory · Jun 2, 2014 – Feb 26, 2015 · Past
Samuele ButeraSenior Vice President, General Manager, Global Respiratory · Since at least Jun 23, 2026
Timothy WhittenPresident & CEO, Director · Dec 1, 2010 – Jun 1, 2012 · Past

Open People

Log in to ask 6ix AI your own questions about Insmed Incorporated.